From May 9 to 11, 2026, the Second General Election Conference of the Cell Medicine Branch of the China Food and Drug Enterprise Quality and Safety Promotion Association (CFDQP) and the Third High-Quality Development Conference of the Cell and Gene Industry were held at the Sanya Mangrove Resort World International Conference Center in Hainan. Professor Shi Yuanyuan, Chairman and General Manager of Shenzhen Cell Valley Group, was invited to attend and presided over both the election conference and the opening ceremony of the industry development conference.

The conference, hosted by the Cell Medicine Branch of CFDQP, focused on key topics including high-quality development of the cell and gene industry, clinical translation of innovative technologies, industrial and supply chain construction, compliant development, and real-world clinical applications. The event brought together experts, scholars, and industry representatives from universities, research institutes, medical institutions, industrial platforms, and enterprises to explore new trends, pathways, and opportunities in the development of the cell medicine industry.

During the election conference, Professor Shi Yuanyuan was reappointed Vice President of the Cell Medicine Branch of CFDQP. This reappointment represents the industry's full recognition of Professor Shi's longstanding dedication to the cell and gene therapy field and his efforts to promote standardized industrial development. It also reflects the industry influence of Shenzhen Cell Valley Group in cell medicine technology innovation, GMP-grade platform construction, clinical research services, and industrial translation.

As a domestic one-stop CRO/CDMO and clinical translation service platform for cell and gene therapy and emerging biomedical technologies, Shenzhen Cell Valley Group has continued to make strategic moves in cell therapy, gene delivery, exosomes, GMP manufacturing, and quality system development, actively supporting medical institutions in conducting compliant clinical research and result translation. With the implementation of the Regulations on the Administration of Clinical Research and Clinical Translational Application of Emerging Biomedical Technologies, the cell medicine industry is entering a critical phase of standardization, systematization, and high-quality development.

Looking ahead, Shenzhen Cell Valley Group will continue to leverage its technology platforms, quality systems, and clinical translation capabilities, actively participating in industry standard-setting and collaborative innovation, accelerating the translation of cell and gene therapy technologies from the research and manufacturing stages to clinical application, and contributing to the high-quality development of China's cell medicine industry.